Menopause News and Research

RSS

Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovary stops producing the hormones estrogen and progesterone.

Gamma Pharmaceuticals, Jugular form new joint venture company

Gamma Pharmaceuticals, Inc. announced the formation of a joint venture company with Jugular, Inc., replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

11 Mar 2010

WebMD Health Exchange platform launched to help consumers get health and wellness support

WebMD Health Corp., the leading source of health information, today announced the launch of WebMD Health Exchange, a new health social networking platform that provides a unique way for consumers to get health and wellness support from the world's largest community of online health-informed consumers.

10 Mar 2010

Rush University Medical Center develops WISHFIT program to help pre-menopausal women reduce visceral fat

Under a $7.1 million grant from the National Institutes of Health, Rush University Medical Center is developing a novel program, called WISHFIT, to help pre-menopausal women reduce visceral fat through a sustained increase in physical activity and reduction in stress.

9 Mar 2010

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.

4 Mar 2010

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

University of Alberta researcher Nese Yuksel says pharmacists could be integral to the education and screening of people for osteoporosis, as pharmacists are easily accessible and are playing a greater role in health promotion and disease prevention.

4 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Ovarian transplant: A viable method for fertility treatment

For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.

25 Feb 2010

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham.

25 Feb 2010

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Post-menopausal women who reported consuming the most daily dietary fat had a 40 percent higher incidence of clot-caused strokes compared to women who ate the least amount, according to research presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

24 Feb 2010

Woman's risk of heart disease intensifies during natural menopause: Study

When women hear the word menopause, they often think about hot flashes, hormone shifts and mood swings. But what about heart disease? Studies show a woman's risk of heart disease intensifies drastically around the time of natural menopause, which for most women is around the age of 50.

24 Feb 2010

Unique resource for families facing hereditary breast and ovarian cancer

When she was forty-two, Joi Morris learned that she has a genetic mutation on a gene known as BRCA2. This meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high.

23 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Conference for Young Women Affected by Breast Cancer: 10th anniversary

2010 marks the 10th anniversary of the only international conference dedicated to the critical issues of young breast cancer survivors and those who care about them. Nearly 1,000 young breast cancer survivors, caregivers and medical professionals from around the world are expected to attend the 10th Annual Conference for Young Women Affected by Breast Cancer, to be held Friday, Feb. 26-Sunday, Feb. 28 at the Sheraton Atlanta Hotel in Atlanta, Ga.

19 Feb 2010

Steroids and weight loss products can accelerate hair loss, says hair loss expert

In a study due to be released next month, the world's leading hair transplant and hair loss expert Dr. Larry Shapiro will show that men and women have been losing their hair from using popular weight loss and work out products that contain whey protein isolate- and it's not just their genes that are to blame.

19 Feb 2010

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc., will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

19 Feb 2010

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

One in eight women diagnosed with breast cancer is younger than 45 when diagnosed, yet their emotional and medical concerns are different than those of women over age 45, as is the impact of their diagnosis on family, friends, partners, colleagues and children.

18 Feb 2010

Menopause News and Research

Further Reading

Gamma Pharmaceuticals, Jugular form new joint venture company

WebMD Health Exchange platform launched to help consumers get health and wellness support

Rush University Medical Center develops WISHFIT program to help pre-menopausal women reduce visceral fat

BioSante Pharmaceuticals enters into securities purchase agreements with Great Point and Deerfield Management

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Ovarian transplant: A viable method for fertility treatment

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Frozen/thawed ovarian tissue transplant: Woman has two children from separate pregnancies

Woman's risk of heart disease intensifies during natural menopause: Study

Unique resource for families facing hereditary breast and ovarian cancer

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Conference for Young Women Affected by Breast Cancer: 10th anniversary

Steroids and weight loss products can accelerate hair loss, says hair loss expert

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News